Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 53

1.

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double-positive lung cancer.

Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Katakami N, Takahashi T, Hasegawa Y, Ko TK, Ong ST, Yano S.

Cancer Sci. 2019 Nov 29. doi: 10.1111/cas.14260. [Epub ahead of print]

2.

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.

Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K, Nishiyama A, Arai S, Yano S, Wang W.

Mol Cancer. 2019 Nov 20;18(1):165. doi: 10.1186/s12943-019-1073-4.

3.

Aberrant Methylation of Tumor Suppressive miRNAs in Bile from Patients With Pancreaticobiliary Diseases.

Ohtsubo K, Miyake K, Arai S, Fukuda K, Yanagimura N, Suzuki C, Otani S, Adachi Y, Tanimoto A, Nishiyama A, Yamashita K, Takeuchi S, Notohara K, Yoshimura K, Yano S.

Anticancer Res. 2019 Oct;39(10):5449-5459. doi: 10.21873/anticanres.13738.

PMID:
31570439
4.

Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.

Kita K, Fukuda K, Takahashi H, Tanimoto A, Nishiyama A, Arai S, Takeuchi S, Yamashita K, Ohtsubo K, Otani S, Yanagimura N, Suzuki C, Ikeda H, Tamura M, Matsumoto I, Yano S.

Cancer Sci. 2019 Oct;110(10):3215-3224. doi: 10.1111/cas.14171.

5.

Clinical Characteristics Associated With Lenvatinib-induced Fistula and Tumor-related Bleeding in Patients With Thyroid Cancer.

Staub Y, Nishiyama A, Suga Y, Fujita M, Matsushita R, Yano S.

Anticancer Res. 2019 Jul;39(7):3871-3878. doi: 10.21873/anticanres.13537.

PMID:
31262915
6.

Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice.

Wang R, Yamada T, Arai S, Fukuda K, Taniguchi H, Tanimoto A, Nishiyama A, Takeuchi S, Yamashita K, Ohtsubo K, Matsui J, Onoda N, Hirata E, Taira S, Yano S.

Mol Cancer Ther. 2019 May;18(5):947-956. doi: 10.1158/1535-7163.MCT-18-0695. Epub 2019 Mar 29.

PMID:
30926637
7.

Comparison of the postoperative analgesic efficacies of intravenous acetaminophen and fascia iliaca compartment block in hip fracture surgery: A randomised controlled trial.

Yamamoto N, Sakura S, Noda T, Nishiyama A, Dan'ura T, Matsui Y, Ozaki T.

Injury. 2019 Oct;50(10):1689-1693. doi: 10.1016/j.injury.2019.03.008. Epub 2019 Mar 16.

PMID:
30904248
8.

Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.

Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S.

Cancer Res. 2019 Apr 1;79(7):1658-1670. doi: 10.1158/0008-5472.CAN-18-2052. Epub 2019 Feb 8.

PMID:
30737231
9.

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.

Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.

Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0.

10.

Phase II Study of Weekly Amrubicin for Refractory or Relapsed Non-small Cell Lung Cancer.

Kitagawa C, Iwasaku M, Kogure Y, Ando M, Yoshioka H, Nishiyama A, Watanabe N, Kunimasa K, Tsubouchi K, Oka S, Saka H.

In Vivo. 2019 Jan-Feb;33(1):163-166. doi: 10.21873/invivo.11453.

11.

Extensive Bilateral Patellar Tendon Ossification in a Spinal Cord Injury Patient.

Yamamoto N, Miki T, Nishiyama A, Dan'ura T, Matsui Y, Ozaki T.

Acta Med Okayama. 2018 Feb;72(1):89-93. doi: 10.18926/AMO/55670.

12.

Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.

Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, Yano S.

Clin Cancer Res. 2018 May 15;24(10):2357-2369. doi: 10.1158/1078-0432.CCR-17-1623. Epub 2018 Feb 20.

13.

Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.

Ikeda S, Yoshioka H, Ikeo S, Morita M, Sone N, Niwa T, Nishiyama A, Yokoyama T, Sekine A, Ogura T, Ishida T.

BMC Cancer. 2017 Nov 28;17(1):797. doi: 10.1186/s12885-017-3814-3.

14.

In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs.

Kita K, Arai S, Nishiyama A, Taniguchi H, Fukuda K, Wang R, Yamada T, Takeuchi S, Tange S, Tajima A, Nakada M, Yasumoto K, Motoo Y, Murakami T, Yano S.

Cancer Med. 2017 Dec;6(12):2972-2983. doi: 10.1002/cam4.1255. Epub 2017 Nov 10.

15.

Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).

Hata A, Katakami N, Hattori Y, Tanaka K, Fujita S, Kotani Y, Nishimura T, Imamura F, Yokota S, Satouchi M, Monden K, Otsuka K, Nishiyama A, Tsubouchi K, Kaneda T, Yoshioka H, Morita S, Negoro S.

Cancer Chemother Pharmacol. 2017 Apr;79(4):689-695. doi: 10.1007/s00280-017-3259-z. Epub 2017 Mar 9.

PMID:
28280972
16.

Reenlargement of radiation necrosis after stereotactic radiotherapy for brain metastasis from lung cancer during bevacizumab treatment.

Furuuchi K, Nishiyama A, Yoshioka H, Yokoyama T, Ishida T.

Respir Investig. 2017 Mar;55(2):184-187. doi: 10.1016/j.resinv.2016.11.001. Epub 2016 Dec 6.

PMID:
28274537
17.

Congenital double-level cervical spondylolysis: a case report and review of the literature.

Yamamoto N, Miki T, Nasu Y, Nishiyama A, Dan'ura T, Matsui Y, Ozaki T.

Eur Spine J. 2017 May;26(Suppl 1):181-185. doi: 10.1007/s00586-017-5005-y. Epub 2017 Feb 28. Review.

PMID:
28247078
18.

Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal.

Kouno M, Nishiyama A, Minabe M, Iguchi N, Ukichi K, Nomura T, Katakura A, Takahashi S.

J Dermatol. 2017 Jun;44(6):695-698. doi: 10.1111/1346-8138.13751. Epub 2017 Feb 2.

PMID:
28150339
19.

Retroperitoneal Metastasis from Lung Adenocarcinoma Mimics Retroperitoneal Fibrosis.

Nishiyama A, Yoshioka H, Ikeo S, Morita M, Sone N, Ikeda S, Yokoyama T, Ishida T.

J Thorac Oncol. 2016 Feb;11(2):266-7. doi: 10.1016/j.jtho.2015.10.023. Epub 2015 Dec 22. No abstract available.

20.

Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.

Konishi S, Arita M, Ito I, Tachibana H, Takaiwa T, Fukuda Y, Watanabe N, Tsubouchi K, Masuda G, Tanaka M, Kourogi Y, Kunimasa K, Nishiyama A, Iwasaku M, Ito A, Tokioka F, Yoshioka H, Hashimoto T, Ishida T.

Intern Med. 2015;54(22):2835-41. doi: 10.2169/internalmedicine.54.4118. Epub 2015 Nov 15.

Supplemental Content

Loading ...
Support Center